×
This small cancer trial led to remission in every single person: 'There were a lot of happy tears'
ADVERTISEMENT

This small cancer trial led to remission in every single person: 'There were a lot of happy tears'

While the study was limited to a particular type of cancer, it's still considered a potential breakthrough and is being heralded as the first of its kind.

Image Source: MSKCancerCenter / Twitter
ADVERTISEMENT

Editor's Note: This article was originally published on June 7, 2022.

In a study conducted at the Memorial Sloan Kettering Cancer Center in New York City, 18 rectal cancer patients who took the same drug found that their cancer completely vanished. Dr. Luis A. Diaz Jr., the lead author of the paper published in the New England Journal of Medicine, stated that this was a first in the history of cancer. While this was a small trial sponsored by GlaxoSmithKline, the results are promising and open up a world of possibilities. Some of those who benefited from the study were even moved to tears. Every single patient is currently in total remission, The New York Times reported.

ADVERTISEMENT



 

According to Dr. Diaz, no other study in which a treatment completely obliterated cancer in every patient presently exists. He affirmed, "I believe this is the first time this has happened in the history of cancer." Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, San Francisco, concurred. He claimed that a complete remission in every single patient is "unheard of." Furthermore, none of the patients had clinically significant complications as a result of the treatment. Approximately one in five patients have some sort of adverse reaction to drugs such as the one the patients took—dostarlimab—known as checkpoint inhibitors.

ADVERTISEMENT



 

Dr. Venook hypothesized that the researchers may have not treated enough patients. He also suggested the cancers treated might have been "just plain different." Over the course of six months, patients were treated with a dose of dostarlimab every three weeks. Each dose cost about $11,000. The study was inspired by a clinical trial Dr. Diaz led in 2017, funded by Merck. Eighty-six people with metastatic cancer took checkpoint inhibitor pembrolizumab for up to two years. Tumors shrank or stabilized in about one-third to one-half of the patients, and they lived longer. Tumors vanished in 10% of the trial’s participants. So, for this study, researchers selected patients who were at a stage much earlier in the course of the disease, that is, before their cancer had a chance to spread. 

ADVERTISEMENT



 

Sascha Roth, then aged 38, was the first patient. She is a runner and helps manage a family furniture store. She first noticed some rectal bleeding in 2019 but otherwise felt fine. Her gastroenterologist informed her she had cancer after performing a biopsy on a tumor found during a sigmoidoscopy. She said, "I completely melted down." Roth was scheduled to start chemotherapy at Georgetown University, but chose to participate in the clinical trial instead. After the trial ended, she planned to move to New York for radiation, chemotherapy and possibly surgery. However, she received unbelievable news.

ADVERTISEMENT



 

"We looked at your scans," Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and a co-author of the paper, told her. "There is absolutely no cancer." Even two years on, Roth remains cancer-free. She did not need further treatment. Remarkably, she was only one of 18 patients who experienced similar results. Dr. Cercek shared, "There were a lot of happy tears." Now, there is immense potential to extend the study to even more patients.

ADVERTISEMENT



 

Recommended for you